title: Primary lymphoma of the liver -- morphological and clinical analysis of 6 cases. Success of aggressive treatment.
abstract: Histological, clinical and immunohistochemical analysis of 6 cases of primary liver lymphomas (PLL) are presented. PLL represents 4.3% of primary malignant liver tumors diagnosed in our department. The patients were relatively young people, who despite the presence of a large tumor, were in good general health status. There were no signs of scirrhosis, and cancer markers were normal. All lymphomas were CD20, CD79a, BAX positive, CD3, CD30, EMA, CD10, CD5, CD59, c-myc, Bcl2, EBV(LMP), CK negative. The proliferation index (Ki67) was high, ranging from 50-100%. In two cases positive staining for Bcl6 and in another one for cyclin D1 was obtained. The major histological type of the tumor was diffuse large B-cell lymphoma. Positive immunohistochemical results with BAX and the lack of Bcl2, c-myc and CD59 are associated with better prognosis. We have not confirmed the value of Bcl6 and CD10 stains as a predictor of poor outcome. Despite clinically advanced stage at the time of diagnosis, if treated appropriately, the primary lymphoma of the liver has relatively good prognosis (five of our patients are alive).
authors.affiliation: Department of Pathology, Medical University of Warsaw, 02-106 Warsaw, Poland. wroblewskabogna@tlen.pl
authors.forename: B
authors.initials: B
authors.lastname: Ziarkiewicz-Wroblewska
authors.forename: B
authors.initials: B
authors.lastname: Gornicka
authors.forename: W
authors.initials: W
authors.lastname: Suleiman
authors.forename: T
authors.initials: T
authors.lastname: Wroblewski
authors.forename: M
authors.initials: M
authors.lastname: Morton
authors.forename: G M
authors.initials: GM
authors.lastname: Wilczynski
authors.forename: H
authors.initials: H
authors.lastname: Heleniak
authors.forename: A
authors.initials: A
authors.lastname: Skwarek
authors.forename: L
authors.initials: L
authors.lastname: Koperski
authors.forename: K
authors.initials: K
authors.lastname: Dudek
authors.forename: M
authors.initials: M
authors.lastname: Krawczyk
authors.forename: W W
authors.initials: WW
authors.lastname: Jedrzejczak
authors.forename: J
authors.initials: J
authors.lastname: Dwilewicz-Trojaczek
authors.forename: A
authors.initials: A
authors.lastname: Wasiutynski
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D018957:CD59 Antigens / Q000378:metabolism; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008113:Liver Neoplasms / Q000175:diagnosis* / Q000378:metabolism / Q000601:surgery*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis* / Q000378:metabolism / Q000601:surgery*; D008297:Male; D011379:Prognosis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D016271:Proto-Oncogene Proteins c-myc / Q000378:metabolism; D033581:Stem Cell Transplantation; D051028:bcl-2-Associated X Protein
chemical_list: D000970:Antineoplastic Agents; C494826:BAX protein, human; D018957:CD59 Antigens; C489427:MYC protein, human; D019253:Proto-Oncogene Proteins c-bcl-2; D016271:Proto-Oncogene Proteins c-myc; D051028:bcl-2-Associated X Protein